GREEN Full allocation — 5 picks deployed.
Volume + catalyst = discovery
Regime: GREEN
The Picks
| Ticker | Scan Price | Gap % | RVOL | Catalyst | ML Hold Prob | ML Expected |
|---|---|---|---|---|---|---|
| ABEO | $5.74 | 6.89 | 30.51 | Fda: Abeona is positioned to collect royalties from Ultragenyx's FDA-approved product, representing a meaningful revenue catalyst. | — | — |
| TEM | $80.00 | 14.33 | 32.49 | Sector: TEM (Teradyne/Tempus AI unclear without ticker context, but assuming semiconductor) rallies with Nasdaq 100 and semiconductor peers as broader tech sector gains on oil decline and yield retreat. | — | — |
| RARE | $14.50 | 12.58 | 23.09 | Fda: Ultragenyx Pharmaceutical received FDA approval for its first Sanfilippo syndrome treatment, driving after-hours stock gains. | — | — |
| MBLY | $8.09 | 3.45 | 30.81 | Other: Mobileye shares are moving on continued follow-through from recent CEO transition and company-specific news flow [via web] | — | — |
| IBRX | $8.42 | 6.45 | 28.33 | Other: ImmunityBio shares are up after a recent 7% jump, with the latest coverage pointing to broader Anktiva patent/label expansion speculation ahead of a lung-cancer conference [via web] | — | — |
The Results
| Ticker | Entry | Entry Time | Exit | Exit Time | Method | P/L | % | Catalyst |
|---|---|---|---|---|---|---|---|---|
| ABEO | $5.69 | 9:35 AM | $5.56 | 1:31 PM | VoV Spike | $-226.46 | -2.28 | Fda: Abeona is positioned to collect royalties from Ultragenyx's FDA-approved product, representing a meaningful revenue catalyst. |
| TEM | $79.09 | 9:35 AM | $77.43 | 3:21 PM | Limit Close | $-208.10 | -2.10 | Sector: TEM (Teradyne/Tempus AI unclear without ticker context, but assuming semiconductor) rallies with Nasdaq 100 and semiconductor peers as broader tech sector gains on oil decline and yield retreat. |
| RARE | $14.41 | 9:35 AM | $14.84 | 3:22 PM | Limit Close | $295.75 | 2.98 | Fda: Ultragenyx Pharmaceutical received FDA approval for its first Sanfilippo syndrome treatment, driving after-hours stock gains. |
| MBLY | $8.10 | 9:35 AM | $7.97 | 10:01 AM | VoV Spike | $-160.68 | -1.60 | Other: Mobileye shares are moving on continued follow-through from recent CEO transition and company-specific news flow [via web] |
| IBRX | $8.32 | 9:35 AM | $8.51 | 3:20 PM | Limit Close | $225.53 | 2.28 | Other: ImmunityBio shares are up after a recent 7% jump, with the latest coverage pointing to broader Anktiva patent/label expansion speculation ahead of a lung-cancer conference [via web] |
Shadow Results
| Ticker | Shadow Entry | Shadow Exit | Exit Time | Method | Shadow P/L | % | Result | Catalyst |
|---|---|---|---|---|---|---|---|---|
| ABEO | $5.69 | $5.56 | 1:31 PM | VoV Spike | $-226.46 | -2.28 | LOSS | Fda: Abeona is positioned to collect royalties from Ultragenyx's FDA-approved product, representing a meaningful revenue catalyst. |
| TEM | $79.09 | $77.43 | 3:21 PM | Limit Close | $-208.10 | -2.10 | LOSS | Sector: TEM (Teradyne/Tempus AI unclear without ticker context, but assuming semiconductor) rallies with Nasdaq 100 and semiconductor peers as broader tech sector gains on oil decline and yield retreat. |
| RARE | $14.41 | $14.84 | 3:22 PM | Limit Close | $295.75 | 2.98 | WIN | Fda: Ultragenyx Pharmaceutical received FDA approval for its first Sanfilippo syndrome treatment, driving after-hours stock gains. |
| MBLY | $8.10 | $7.97 | 10:01 AM | VoV Spike | $-160.68 | -1.60 | LOSS | Other: Mobileye shares are moving on continued follow-through from recent CEO transition and company-specific news flow [via web] |
| IBRX | $8.32 | $8.51 | 3:20 PM | Limit Close | $225.53 | 2.28 | WIN | Other: ImmunityBio shares are up after a recent 7% jump, with the latest coverage pointing to broader Anktiva patent/label expansion speculation ahead of a lung-cancer conference [via web] |
Things to Explore
Interested in our research, validation methodology, and trading system?
Get in TouchWork With Diana
Need a context architect to scaffold your AI agents and facilitate structured learning?
Visit goddev.aiThis post is part of a series documenting MorningEdge's development in real time. The knowledge base contains 0 books, papers, and lab reports totaling 0+ searchable chunks. The trading system described is paper trading only — no real capital is at risk.